Business
Ensysce Biosciences Provides Corporate Update
Answers Recently Asked QuestionsSAN DIEGO, CA / ACCESSWIRE / February 23, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a
About this update from Ensysce Biosciences, Inc.
[{"type":"text","content":"Answers Recently Asked QuestionsSAN DIEGO, CA / ACCESSWIRE / February 23, 2023 / Ensysce Biosciences, Inc. (\"Ensysce\" or the \"Company\") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today issued a letter to shareholders from Chief Executive Officer, Dr. Lynn Kirkpatrick, to address the Company's most recent frequently asked questions.Dear Fellow Shareholders,As a clinical stage biotech company working through clinical development, our opportunities to touch base with our investor community are largely tied to Company milestones and the announcement of associated clinical data. Given our progress throughout the past year, I wanted to update shareholders and supporters of our work, addressing some questions we have recently received regarding our development progress and timelines.What is our mission?Our mission, simply put, is to improve drug safety. We have specific expertise in reducing abuse and overdose. We believe our technology has broad applications, and our first goal is to improve opioid analgesics by delivering safer options, thereby impacting the opioid crisis.Are opioid products necessary?Yes, we and many experts believe they are very necessary. Opioids have been used for over 3,000 years and are highly effective drugs to treat severe pain. Today opioids are still the most effective therapies available for many pain conditions. There have been extensive efforts to replace them without success. Due to the way conventional opioids work in the body, however, their use can lead to abuse and, unfortunately, overdose.Why is Ensysce focusing on opioids?Several companies have tried to improve the way opioids are delivered by formulating to release the drug slowly, referred to as abuse-deterrent formulations or ADFs. ADFs have been prescribed over the last two decades, but this approach has not solved the problem. Ensysce's technology is completely different from these formulated products and we believe it is perfectly suited to reduce the ability to abuse prescription drugs.How does your technology work?Our technology chemically modifies the opioid to make it inactive until swallowed. This chemistry is difficult to overcome by manipulation in order to abuse our products. That doesn't mean it's impossible, but our clinical...